Navigating Drug Pricing Policies

This chapter discusses the complexities surrounding a most favored nation policy on drug pricing, focusing on the lack of communication between health authorities and pharmaceutical companies. It also explores the potential for a direct-to-consumer sales model and the challenges related to government pricing guidelines and insurance implications.